Metabolic reprogramming is a fundamental hallmark of cancer, enabling tumors to sustain rapid proliferation and evade treatment by dynamically shifting nutrient acquisition and energy signaling. Recent studies in colorectal cancer (CRC) demonstrated that tumor and immune cells within the tumor microenvironment (TME) undergo cell-cell fusion to generate tumor-immune hybrid cells that inherit the functional transcriptomes of both parental lineages. Together, our study seeks to elucidate the metabolic heterogeneity of tumor-immune hybrids and highlight potential therapeutic targets to mitigate hybrid cell formation and halt disease progression.
